News
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study "Combined Metabolic Activators Accelerates Recovery in...
ChromaDex Announces $25 Million Private Placement of Common Stock
Private placement led by new international investor LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement...
ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2020. The financial results will be reported in a press release...
New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function
A new clinical study published in Cell Press Sneak Peek finds nutritional protocol including nicotinamide riboside (NR) significantly decreases liver fat, improves liver function LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study...
ChromaDex to Present at Benzinga’s Inaugural Small Cap Conference in December 2020
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the December 2020 Benzinga Small Cap Conference on Wednesday, December 9, 2020 at 11:15am ET (8:15am PT). This inaugural Small Cap Conference is a day dedicated to...
ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)
Researchers to compare milk production among mothers of preterm infants while receiving ChromaDex's ingredient nicotinamide riboside (Niagen®, or NR) LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of...
ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership
ChromaDex and Watsons Hong Kong launch new TRU NIAGEN® EX stick packs for on-the-go consumers in new delivery method LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong,...
ChromaDex Corporation Reports Third Quarter 2020 Financial Results
Revenue for the Three-Month Period Ended September 30, 2020 Totals $14.2 Million, up 18% Year-over-Year, with Gross Margin of 59.6%, and Lower Operating Expenses LOS ANGELES - ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third...
ChromaDex to Report Third Quarter 2020 Financial Results on Wednesday, November 4, 2020
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2020. The financial results will be reported in a press...
New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice
New preclinical study finds boosting NAD+ with nicotinamide riboside alleviated telomere damage, providing protective effect to DNA strands LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology...